Chapter 5. Management of Elevated Low-Density Lipoprotein Cholesterol

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4 and
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch5

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

How to Cite

Toth, P. P. and Maki, K. C. (2008) Management of Elevated Low-Density Lipoprotein Cholesterol , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch5

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

Keywords:

  • low-density lipoprotein cholesterol;
  • LDL-C - primary cholesterol target;
  • carotid artery disease (CAD);
  • multiple risk factor intervention trial (MRFIT);
  • Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT);
  • Heart Protection Study (HPS);
  • elevated LDL-C management;
  • Liver function tests (LFTs) and baseline measurement;
  • aggressive LDL-C reduction

Summary

This chapter contains sections titled:

  • Relationship between LDL-C and Risk for Cardiovascular Events

  • Clinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk

  • Genetic Disorders Associated with Elevated LDL-C

  • Atherogenic Impact of LDL-C

  • Management of Elevated LDL-C

  • Summary

  • Controversy: How Low Should We Go?

  • Controversy: Risks and Benefits of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy

  • Controversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on “How Low You Go” or also on “How You Get There”?